Vol. 5 No. 1 (2025)
Reimbursement Reviews

Ivosidenib (Tibsovo)

decorative image of the issue cover

Published January 21, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses ivosidenib (Tibsovo), 250 mg, tablet, oral.
  • Indication: Ivosidenib in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia with an IDH1 R132 mutation who are not eligible to receive intensive induction chemotherapy.